Metabolomics Moving Towards A Better Understanding of Desmoid Tumors
|
|
- Diane Stevens
- 5 years ago
- Views:
Transcription
1 Metabolomics Moving Towards A Better Understanding of Desmoid Tumors Kelly Mercier, Ph.D NIH Eastern Regional Comprehensive Metabolomics Resource Core at RTI International RTI International is a registered trademark and a trade name of Research Triangle Institute.
2 What Is RTI International? RTI is an independent, nonprofit institute that provides research, development, and technical services to government and commercial clients worldwide. Our mission is to improve the human condition by turning knowledge into practice.
3 Notable Achievements Taxol and camptothecin Speech processing for cochlear implants Survey technology (ACASI) Wind shear avoidance system Indoor air quality research Neglected tropical disease control Clean coal technology Malaria, HIV, and tuberculosis prevention and treatment programs
4 Metabolomics Metabolomics involves the analysis of the low molecular weight complement of cells, tissues, or biological fluids. Metabolomics makes it feasible to uniquely profile the biochemistry of an individual or system. Metabonomics is used to determine the pattern of changes (and related metabolites) arising from disease, dysfunction, disorder, or from the therapeutic or adverse effects of xenobiotics Mammalian, plant, and aquatic species This leading-edge method has come to the fore to reveal biomarkers for the early detection and diagnosis of disease, to monitor therapeutic treatments, and to provide insights into biological mechanisms.
5 NIH Common Fund Metabolomics Cores NIH Metabolomics Centers Ramp Up November 4, 2013 Issue - Vol. 91 Issue 44 Chemical & Engineering News. by Jyllian Kemsley
6 Research Collaborations Investigational Areas Treatment Intervention Nutrition Fat, Soy, Casein, Rice Exposure Metals, PAHs, Wood Smoke, PM2.5 Mental Health Schizophrenia, Bipolar Disorder, Anxiety Development Reproduction Cancer Climate Change Barth Syndrome Infection Opthamology Sample Types Kidney Liver Brain Ovary Eye Lung Muscle Serum Plasma Feces Urine Saliva Mussel Rice Sample Origin Humans Elderly Adults Children Neonates Pregnancy Animal models Primates Rodents Aquatic Insects Cells
7 Women s and Children s Health Pediatric Glomerular Disease Bill Smoyer Neonatal Acute Kidney Injury Pat Brophy David Askenazi Barth Syndrome Hilary Vernon Arsenic, in utero exposure, diabetes Rebecca Fry PAH, in utero exposure, birth outcomes, MDI Fredrica Perea Pregnancy Complications Michelle Williams Phthalates and Pediatric Obesity Leo Transnade New award Childhood Infections Margaret Karagas New award Pediatric Obesity David Collier in utero exposure, obesity Catherine Hoyo
8 Desmoid Tumor Cell Lines Dr. Ben Alman (Duke University) and the Desmoid Collaboration for a Cure Dr. Ben Alman Desmoid Collaboration for a Cure Progress: Screened 9 primary cell lines 5 different compound libraries 45 compounds inhibited cell proliferation in desmoid tumors by greater than 50% with no effect on normal fibroblast proliferation All either approved for use in patients or have the potential to be rapidly developed for patient care. Mushriq Al- Jazrawe RTI has initiated a collaboration with Dr. Alman and his group
9 Metabolomics Meets Desmoid Tumors Novel Therapeutics Use broad spectrum and targeted metabolomics to investigate how the cell lines respond to efficacious drugs identified by the Desmoid Collaboration for a Cure What effects are different for each desmoid-normal fibrobast pair for all drugs? What effects are the same for each desmoid-normal fibrobast pair for all drugs?
10 Metabolomics Meets Desmoid Tumors Basic Biology Use broad spectrum and targeted metabolomics to investigate: Primary desmoid tumor cell lines Matched normal fibroblast cell lines Unaffected fibroblast cell line What biochemical processes differentiate the matched desmoid tumors from the adjacent fibroblast? What biochemical differences are there between the matched fibrobasts and the unaffected?
11 Metabolomics Meets Desmoid Tumors Recurrence and Prediction Biomarkers Use broad spectrum and targeted metabolomics to investigate tissue or cells associated with a primary dissections verse N+1 dissections What metabolites define the primary mass verses the N+1? Can metabolites be found that predict likelihood of regrowth? Use broad spectrum and targeted metabolomics to predict response to treatment Partner with a clinician running a clinical trial Identify patients that are high responders and low responders
12 1 H NMR Spectrum of Primary Cell Line 233 RTI RCMRC Preliminary Data Glycine Carnitine Glutamate Glutamine Lactate Threonine myo-inositol Alanine Creatine phosphate Lactate Glucose Threonine Creatine Creatinine Methionine N-acetyl amino acids Arginine Lysine BCAA
13 1 H NMR Spectrum of Primary Cell Line 233 and 235 RTI RCMRC Preliminary Data Media from Primary Cell Line 233 Media from Primary Cell Line 235 Blank Media Lactate Succinate Pyruvate BCAA Glutamate Alanine Propylene Glycol 3-HBA 3-Methyl-2- oxovalerate
14 Metabolomics and Barth Syndrome Rare disease characterized by dilated cardiomyopathy skeletal myopathy neutropenia short stature Transmitted from mother to son as an X-linked genetic condition as mutation of the tafazzin (TAZ or G4.5) A RTI RCMRC Pilot and Feasibility Study: NMR and LC-MS analysis of plasma Further define metabolic and molecular pathways involved in metabolism Identify potential targets for treatment 23 Barth Syndrome patients and 11 age-matched controls Dr. Hilary Vernon Johns Hopkins U. Dr. Yana Sandlers Cleveland State U.
15 NMR and LC-MS of plasma from Barth Syndrome Cases and Healthy Subjects NMR NMR Library Matched Bins VIP p-value* 3-Hydroxybutyrate Carnitine, Lipids/Fatty Acids Creatinine, Overlap Lipids/Fatty Acids (4) Methionine Proline, Lipids/Fatty Acids Unsaturated Lipids/Fatty Acids (2) VLDLs VLDLs, Unknown LC-MS Biocrates p180 assay Acyclcarnitines, Amino acids, Biogenic amines, and Glycerophospholipids all differentiated the Barth Syndrome patients from the controls. Control- Case-
16 Metabolomics and Target Identification Distribution of Biochemical Functions
17 RTI - RCMRC Susan Sumner Center Director Wimal Pathmasiri NMR & GC-MS Tim Fennell In vivo Metabolism Susan McRitchie Data Analysis Zach Acuff Biostatistics Bob Clark Genetics Jocelin Spruill GC-MS Jim Carlson LC- and GC-MS Jessica Gooding LC-MS Andrew Novokhatny Quality Control Tammy Cavallo Quality Control Ninell Mortensen Microbiology Kelly Mercier NMR Jason Burgess NMR Rod Snyder LC-MS Delisha Stewart Cell Biology Keith Levine Metallomics James Harrington Metallomics
18 Funding NIDDK: NIH Common Fund 1U24DK097193: NIDDK: Sumner, RTI, PI NIH Eastern Regional Comprehensive Metabolomics Resource Core NIEHS U2C ES : Timothy Fennell, PI Children s Health Exposure Analysis Resource (CHEAR) Hub NIGMS: NIH Common Fund 5R25GM103802: Martin Kohlmeier, UNC-CH, PI Online learning platform introducing clinicians and researchers to metabolomics. NEI: NIH Common Fund R01EY012224: Ellen Weiss, UNC-CH, PI Desensitization of Cone Visualization Signaling Pathways. NHLBI: NIH Common Fund HHSN C:Herb Seltzman, PI; Metabolite Standards Synthesis Core NIDDK: 1UMDK : PI s: William Smoyer, Nationwide Children s Hospital & Larry Greenbaum, Emory. Integrated Proteomics and Metabolomics for Pediatric Glomerular Disease NIEHS: U19ES year 5: PI: Timothy Fennell Estimating Human Health Risks from Exposure to Nanoparticles NCATS: UL1TR00111: PI: John Buse (UNC-CH), North Carolina Translational and Clinical Sciences Institute- NCTraCS
Wimal Pathmasiri, Rodney Snyder NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC)
NMR Hands On UAB Metabolomics Training Course July 17-21, 2016 Wimal Pathmasiri, Rodney Snyder NIH Eastern Regional Comprehensive Metabolomics Resource Core (RTI RCMRC) is a trade name of Research Triangle
More informationNMR Data Pre-processing
NMR Data Pre-processing UAB Metabolomics Training Course July 17-21, 2017 Wimal Pathmasiri and Delisha Stewart NIH Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC) Department of Nutrition
More informationNMR Data Analysis Exercise
NMR Data Analysis Exercise UAB Metabolomics Training Course July 17-21, 2017 Wimal Pathmasiri and Delisha Stewart NIH Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC) Department of Nutrition
More informationMetabolomics to Provide Biomarkers and Mechanistic Insights
Metabolomics to Provide Biomarkers and Mechanistic Insights Susan Sumner, PhD Director NIH Eastern Regional Comprehensive Metabolomics Resource Core Systems and Translational Sciences Program ssumner@rti.org
More informationStealth BioTherapeutics Mission:
The following is a summary of a live presentation offered through joint collaboration with UMDF, MitoAction and the Foundation for Mitochondrial Medicine to the mitochondrial disease patient and family
More informationOrgans on Chips: The Future of Translational Research
Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug
More informationNIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts)
NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts) 1. NCI (National Cancer Institute) cancer cause, prevention, detection, diagnosis, treatment and control 2. NIAID
More informationMetabolomics S.M.Shotorbani, V. A. Suliman
13 International Journal of Advance Research, IJOAR.org Volume 1, Issue 1, January 2013, Online: Metabolomics S.M.Shotorbani, V. A. Suliman ABSTRACT A brief review on metabolomics, a new field being explored,
More informationStatistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice
Statistically Integrated Metabonomic-Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice Mattias Rantalainen, Olivier Cloarec, Olaf Beckonert, I. D. Wilson, David Jackson, Robert Tonge,
More informationMetabolomics to Provide Biomarkers and Mechanistic Insights
Metabolomics to Provide Biomarkers and Mechanistic Insights Susan Sumner, PhD Director NIH Eastern Regional Comprehensive Metabolomics Resource Core Systems and Translational Sciences Program RTI International
More informationMetabolomics: Techniques and Applications ABRF
Metabolomics: Techniques and Applications ABRF Sacramento, CA March 23, 2010 Overview Metabolomics Definitions Representative Project Sarcosine, a prostatic cancer biomarker Technical overview/ How we
More informationWhat is the Future of NIH funded Clinical Research in IBD?
IBD Clinical Trials Workshop What is the Future of NIH funded Clinical Research in IBD? Stephen P. James, M.D. January 13-14, 2017 Future? FY 2015 NIH Awards for IBD related research 338 Awards $128 Million
More informationNorth Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA)
North Carolina Translational and Clinical Sciences (NC TraCS) Institute Integrated home of the Clinical and Translational Science Awards (CTSA) What is Translational Research? Translational research includes
More informationNATIONAL INSTITUTES OF HEALTH
NATIONAL INSTITUTES OF HEALTH (dollars in millions) 2011 2012 2013 2013 +/- 2012 Institutes National Cancer Institute... 5,050 5,066 5,069 +3 National Heart, Lung and Blood Institute... 3,065 3,075 3,076
More informationLETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department
Adrienne Pervès adrienne.perves@cea.fr Deputy Director LETI Technologies for Biology and healthcare Department LETI-HEALTH Micro- NanoTechnologies for Healthcare and Biology MISSION AND EXPERTISE Focused
More informationAnalyzing and utilizing NIH award data Perry Kirkham, Ph.D.
Analyzing and utilizing NIH award data Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 What decisions can be informed through the use of NIH data?
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS. Torbjörn Lundstedt Professor in Chemometrics C.S.O.
A cure o m i c s ENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS Torbjörn Lundstedt Professor in Chemometrics C.S.O. AcureOmics AB Thessaloniki, Greece, 19 th of May, 2016 1
More informationGovernment Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER
www.g2gconsulting.com Government Bioscience Grant (GBG) Report October 2016 Title (Agency) Opp. Number Description Deadline Funding Level Eligibility Link BROAD AGENCY ANNOUNCEMENTS 1. Advanced Research
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationNew test for transplant rejection on the horizon
December 6, 2004 New test for transplant rejection on the horizon Vancouver Researchers at St. Paul s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate
More informationThe Five Key Elements of a Successful Metabolomics Study
The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and
More informationFP7 Cooperation Work Programme: Health-2011 Topics and contact points
FP7 Cooperation Work Programme: Health-2011 Topics and contact points Date of publication: 30 July 2010 Call identifiers: Indicative budgets Deadlines FP7-HEALTH-2011-single-stage EUR 160.5 million 10
More informationIGPNS Recommended Electives List
IGPNS Recommended Electives List Animal Science 414: Ruminant Nutrition Integrates basic nutrition concepts and ration balancing skills by teaching students to balance and troubleshoot rations for various
More informationNIMH Updates and Research Priorities
NIMH Updates and Research Priorities ASCP Annual Meeting May 31, 2018 Shelli Avenevoli, Ph.D. Disclosure of Affiliations No conflicts of interest or disclosures 2 Agenda NIH and NIMH Updates NIMH Intervention
More informationOur website:
Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationChristopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic
More informationThe National Institutes of Health ICs: mission and funding strategies
The National Institutes of Health ICs: mission and funding strategies Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 NIH Workshop topics and dates
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationClinical Trials Development Resource for Hematologic Disorders (U24)
Clinical Trials Development Resource for Hematologic Disorders (U24) Diane Catellier, DrPH RTI International RTI International is a trade name of Research Triangle Institute. www.rti.org What is the U24
More informationMetabolomics. A GlobalMarketOverview. TechnologiesandApplications. ReportCode:BT004 Pages:508 Charts:306 Price:Sample
I I Biotechnology Metabolomics TechnologiesandApplications A GlobalMarketOverview Thereportreviews,analyzesandprojects theglobalmarketformetabolomictechnologies andapplicationsfortheperiod2010-2020. Published:Nov2014
More informationMETABOLIC PROFILING AND SIGNATURES IN ALS. Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina
METABOLIC PROFILING AND SIGNATURES IN ALS Rima Kaddurah-Daouk, Ph.D. Metabolic Profiling: Pathways in Discovery Dec 2-3, 2002 North Carolina Metabolomics is the newest Omics science DNA Genomics RNA Transcriptomics
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationBIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus
Course Director: BIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus Location and meeting times Mo/We 10:30am 11:50am, George Auditorium Martin Tenniswood, PhD Department of Biomedical Sciences
More informationDisruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health
Disruptive Innovation at the NIH Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health NIH: Steward of Medical and Behavioral Research for the Nation Science in
More informationPATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE
PATHWAYS TO BIOMARKER QUALIFICATION AND ACCEPTANCE CHRISTOPHER LEPTAK, M.D., PH.D. DIRECTOR, OND REGULATORY SCIENCE PROGRAM CO-DIRECTOR, BIOMARKER QUALIFICATION PROGRAM NASH Biomarkers Workshop May 5,
More informationRequest for Projects for Wake Forest Brain Tumor SPORE Application
1 Request for Projects for Wake Forest Brain Tumor SPORE Application This RFA is for three types of projects that will be taken into consideration for inclusion in the Wake Forest Brain Tumor Specialized
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationNational Institutes of Health 101
National Institutes of Health 101 Perry Kirkham, Ph.D. Office of the Executive Vice President for Research and Partnerships E-mail: pkirkham@purdue.edu Phone: 63645 Questions and topics to be addressed
More informationNewborn Screening Policy Development in the United States
Newborn Screening Policy Development in the United States The Changing Scene and The Way Forward in the Genomic Era Association of Public Health Laboratories 2013 Annual Meeting Raleigh, North Carolina
More informationThe Power to Cure: Therapeutic Innovation in Academia
The Power to Cure: Therapeutic Innovation in Academia Leslie Molony, Ph.D. November 7, 2011 Sanford-Burnham Medical Research Institute: a Non Profit Basic Research Institute Santa Barbara Est. 2006 La
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationCapabilities & Services
Capabilities & Services Accelerating Research & Development Table of Contents Introduction to DHMRI 3 Services and Capabilites: Genomics 4 Proteomics & Protein Characterization 5 Metabolomics 6 In Vitro
More informationExposome: Challenges and Opportunities in the study of NCDs
Imperial College London Exposome: Challenges and Opportunities in the study of NCDs Paul Elliott Imperial College London School of Public Health Disclosures (Paul Elliott) Dr Elliott receives funding from
More informationWeekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts January 11, 2019 Table of Contents (TOC) Web Version
Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts January 11, 2019 Table of Contents (TOC) Web Version Notices Notice of Information: Updates and clarifications of several
More informationIntroduction to Basic Human Genetics. Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland
Introduction to Basic Human Genetics Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and Reproductive Health Research Geneva
More informationAdis Journals and Newsletters The premier collection of drug-focused medical journals
adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,
More informationStem Cells: Introduction and Prospects in Regenerative Medicine.
Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,
More informationPart 1 examination. Clinical Biochemistry: First paper. Tuesday 26 September Candidates must answer FOUR questions only
Tuesday 26 September 2017 Candidates must answer FOUR questions only Time allowed: three hours 1. Outline how pre-analytical factors can affect the results of clinical biochemistry tests and describe what
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationProteomics and Metabolomics in Psychiatry
Proteomics and Metabolomics in Psychiatry Advances in Biological Psychiatry Vol. 29 Series Editors W.P. Kaschka Ravensburg W.F. Gattaz São Paulo Proteomics and Metabolomics in Psychiatry Volume Editor
More informationPatient Focused Drug Development 2.0
Patient Focused Drug Development 2.0 September 15, 2015 Pat Furlong, PPMD ParentProjectMD.org Understanding the Duchenne Muscular Dystrophy Environment 2 About Duchenne muscular dystrophy X-linked, pediatric
More informationAll research lines at the LMU have a strong methodological focus
Content: Genetic Epidemiology and Statistical Genetics in Complex Diseases... 2 Molecular Epidemiology of Complex Phenotypes... 2 Clinical Trials and Translational Medicine... 3 Clinical Epidemiology and
More informationFour new Gillings Innovation Labs awarded
Four new Gillings Innovation Labs awarded February 25, 2016 Four teams of researchers at the UNC Gillings School of Global Public Health have been awarded new funding for Gillings Innovation Labs (GILs),
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationMRC-NIHR National Phenome Centre
MRC-NIHR National Phenome Centre PROFESSOR JEREMY NICHOLSON Director of the MRC-NIHR National Phenome Centre OUR PHILOSOPHY Disease risk at the individual and population level is determined by complex
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationLecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry
Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationGenomics Changing the Way Care is Delivered
Genomics Changing the Way Care is Delivered Eric P. Hoffman, PhD Director, Center for Genetic Medicine Research A. James Clark Professor of Molecular Genetics Children s National Medical Center Washington,
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationPage 1 of 5 Message from the Director: As the summer kicks off, many of us will renew our focus on research and scholarship. Towards this goal, we draw your attention to a several upcoming events and opportunities
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationThe Role of the NIH Clinical Center in Translational and Clinical Research
The Role of the NIH Clinical Center in Translational and Clinical Research International Conference on Engineering Science and Technology 2014 John I. Gallin, M.D. Director, NIH Clinical Center Associate
More informationAsterand Bioscience Strategic Alliances
Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in
More informationProgress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process
Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Petra Kaufmann, MD, MSc, FAAN Director, Division of Clinical Innovation NCATS/NIH DIA MEETING, WASHINGTON
More information6th Form Open Day 15th July 2015
6th Form Open Day 15 th July 2015 DNA is like a computer program but far, far more advanced than any software ever created. Bill Gates Welcome to the Open Day event at the Institute of Genetic Medicine
More informationOverview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014
Genetics where is it leading us? Jill Goldman, MS, MPhil, CGC Taub Institute Columbia University Medical Center Overview Why are there so many research studies on the genetics of? How much of is genetic?
More informationTotal urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks
September 5, 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II
More informationThe Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC
The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationCIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator
FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:
More informationClinical and Translational Science Award (CTSA) program director/principal investigator
Splemental digital content for Kost RG, Leinberger-Jabari A, Evering TH, et al. Helping basic scientists engage with community Splemental Digital Appendix 1 Organizational Chart for Community-Engaged Research
More informationMetabolomics. Primary Molecules. Secondary Molecules TMAO. creatinine citrate. hippurate. allantoin creatinine taurine. urea water.
Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (22) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationBiomolecular Characterization for Rational Drug Design. Maria João Romão
Biomolecular Characterization for Rational Drug Design Maria João Romão UCIBIO@REQUIMTE Applied Molecular Biosciences Unit Chemistry Department - FCT NOVA mjr@fct.unl.pt / http://sites.fct.unl.pt/xtal
More informationNature Reviews: Drug Discovery Nicholson et al. (2002)
Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (2002) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationIncorporating New TB Diagnostics into RePORT
Incorporating New TB Diagnostics into RePORT Susan Dorman Johns Hopkins University School of Medicine REPORT MEETING, DURBAN, JULY 2016 MACS designed to: 1. Elucidate the natural history of the infection
More informationDBT Embarks on Pre-term Birth Program
DBT Embarks on Pre-term Birth Program Preamble: Program on pre-term birth is the first inter-institutional program on maternal-infant health and spontaneous pre-term birth sciences in India funded by the
More informationSubmission Limitations: Emory University may submit only 1 application for this program
National Institutes of Health NIAMS Rheumatic Diseases Research Core Centers (P30) Website: http://grants.nih.gov/grants/guide/rfa-files/rfa-ar-12-002.html Agency Deadline: February 1, 2012 (Letters of
More informationUp Close and Personal
Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent
More informationAbout ICarbonX. Learn more:
About ICarbonX icarbonx is a technology company, combining advances in artificial intelligence, multi-omics and experience to fundamentally change how people understand their present to optimize their
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationANIMAL BEHAVIOR CORE - We need your input!!!
Page 1 of 5 Message from the Director April tends to be a busy month for all; students and faculty are preparing for the end of the semester. The Integrative Neuroscience Center Leadership Team has started
More informationNature Reviews: Drug Discovery Nicholson et al. (2002)
Metabolomics Nature Reviews: Drug Discovery Nicholson et al. (2002) Efficacy Toxicity Primary Molecules Secondary Molecules Filtration Resorption Dilution Concentration TMAO hippurate allantoin creatinine
More informationCTSA collaborators. Planning Pilot Studies in. Science. The origin of this talk. Summary. Charity G. Moore, PhD, MSPH July 7, 2011
Planning Pilot Studies in Clinical and Translational Science CTSA collaborators Rickey E. Carter (Mayo) Paul lnietert t (MUSC) Paul Stewart (UNC) Charity G. Moore, PhD, MSPH July 7, 2011 The origin of
More informationA bold vision for 2025
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015
More informationCompeting & Collaborating to Achieve Successful Drug Repositioning
Competing & Collaborating to Achieve Successful Drug Repositioning Noel Southall, Ph.D. National Human Genome Research Institute National Institutes of Health July 14, 2011 NIH Chemical Genomics Center
More informationSmall Interfering RNA s Molecular biology and use in therapy
Small Interfering RNA s Molecular biology and use in therapy Dr Stuart Hamilton - NHMRC Early Career Fellow Serology and Virology Division, SEALS Microbiology, Prince of Wales Hospital; School of Women
More informationPMHDC Principal Investigators:
OVERVIEW Precision Medicine (PM) is an approach to disease detection, prevention, and treatment based on people s individual differences. The Precision Medicine and Health Disparities Collaborative (PMHDC,
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More information